风湿免疫科指南

订阅

MedSci主页 / 所有栏目 / 风湿免疫科指南

2021 CRA建议：自身免疫性风湿病患者应用COVID-19疫苗

2021-05-15 加拿大风湿病学协会 J Rheumatol.2021 May 15;jrheum.210288.

自身免疫性

2021年5月，加拿大风湿病学协会(CRA)发布了自身免疫性风湿病患者应用COVID-19疫苗建议，CAR专家组建议在自身免疫性风湿病患者中应用COVID-19疫苗，并提供相应指导建议。

中文标题：

2021 CRA建议：自身免疫性风湿病患者应用COVID-19疫苗

英文标题：

Canadian Rheumatology Association recommendation for the use of COVID-19 vaccination for patients with autoimmune rheumatic diseases

发布机构：

加拿大风湿病学协会

发布日期：

2021-05-15

简要介绍：

2021年5月，加拿大风湿病学协会(CRA)发布了自身免疫性风湿病患者应用COVID-19疫苗建议，CAR专家组建议在自身免疫性风湿病患者中应用COVID-19疫苗，并提供相应指导建议。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 CRA建议：自身免疫性风湿病患者应用COVID-19疫苗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=df43e1c00210906c, title=2021 CRA建议：自身免疫性风湿病患者应用COVID-19疫苗, enTitle=Canadian Rheumatology Association recommendation for the use of COVID-19 vaccination for patients with autoimmune rheumatic diseases, guiderFrom=J Rheumatol.2021 May 15;jrheum.210288., authorId=0, author=, summary=2021年5月，加拿大风湿病学协会(CRA)发布了自身免疫性风湿病患者应用COVID-19疫苗建议，CAR专家组建议在自身免疫性风湿病患者中应用COVID-19疫苗，并提供相应指导建议。, cover=https://img.medsci.cn/2021529/1622303856919_2020535.jpg, journalId=0, articlesId=null, associationId=1157, associationName=加拿大风湿病学协会, associationIntro=null, copyright=0, guiderPublishedTime=Sat May 15 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年5月，加拿大风湿病学协会(CRA)发布了自身免疫性风湿病患者应用COVID-19疫苗建议，CAR专家组建议在自身免疫性风湿病患者中应用COVID-19疫苗，并提供相应指导建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=1988, tagName=自身免疫性)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1988, guiderKeyword=自身免疫性, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6591, appHits=147, showAppHits=0, pcHits=444, showPcHits=6444, likes=0, shares=10, comments=5, approvalStatus=1, publishedTime=Sun May 30 00:27:37 CST 2021, publishedTimeString=2021-05-15, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sat May 29 23:57:48 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sun Dec 31 04:38:41 CST 2023, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 CRA建议：自身免疫性风湿病患者应用COVID-19疫苗.pdf)])
2021 CRA建议：自身免疫性风湿病患者应用COVID-19疫苗.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1198074, encodeId=5ee911980e450, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=720a6147540, createdName=ms4000000271720178, createdTime=Mon Feb 28 16:47:00 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191146, encodeId=21da119114679, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e1c5729764, createdName=ms8000000813000467, createdTime=Tue Feb 08 19:45:47 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055357, encodeId=4ce9105535ef1, content=很有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Mon Sep 27 14:33:41 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969901, encodeId=9c2b969901ff, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/LTwppeI4Hta4DDWCPCckmNtbmha6NQP5o7uMk2wicw0QnP4qKsM7hgcjGI9NYN3FLPmgGzMib0mGt7kuZUm9Xwlg/132, createdBy=ab435250494, createdName=lly3676, createdTime=Mon May 31 18:13:04 CST 2021, time=2021-05-31, status=1, ipAttribution=)]
    2022-02-28 ms4000000271720178

    谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1198074, encodeId=5ee911980e450, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=720a6147540, createdName=ms4000000271720178, createdTime=Mon Feb 28 16:47:00 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191146, encodeId=21da119114679, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e1c5729764, createdName=ms8000000813000467, createdTime=Tue Feb 08 19:45:47 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055357, encodeId=4ce9105535ef1, content=很有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Mon Sep 27 14:33:41 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969901, encodeId=9c2b969901ff, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/LTwppeI4Hta4DDWCPCckmNtbmha6NQP5o7uMk2wicw0QnP4qKsM7hgcjGI9NYN3FLPmgGzMib0mGt7kuZUm9Xwlg/132, createdBy=ab435250494, createdName=lly3676, createdTime=Mon May 31 18:13:04 CST 2021, time=2021-05-31, status=1, ipAttribution=)]
    2022-02-08 ms8000000813000467

    好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1198074, encodeId=5ee911980e450, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=720a6147540, createdName=ms4000000271720178, createdTime=Mon Feb 28 16:47:00 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191146, encodeId=21da119114679, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e1c5729764, createdName=ms8000000813000467, createdTime=Tue Feb 08 19:45:47 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055357, encodeId=4ce9105535ef1, content=很有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Mon Sep 27 14:33:41 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969901, encodeId=9c2b969901ff, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/LTwppeI4Hta4DDWCPCckmNtbmha6NQP5o7uMk2wicw0QnP4qKsM7hgcjGI9NYN3FLPmgGzMib0mGt7kuZUm9Xwlg/132, createdBy=ab435250494, createdName=lly3676, createdTime=Mon May 31 18:13:04 CST 2021, time=2021-05-31, status=1, ipAttribution=)]
    2021-09-27 13f0c37dm61暂无昵称

    很有帮助

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1198074, encodeId=5ee911980e450, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=720a6147540, createdName=ms4000000271720178, createdTime=Mon Feb 28 16:47:00 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191146, encodeId=21da119114679, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e1c5729764, createdName=ms8000000813000467, createdTime=Tue Feb 08 19:45:47 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055357, encodeId=4ce9105535ef1, content=很有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Mon Sep 27 14:33:41 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969901, encodeId=9c2b969901ff, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/LTwppeI4Hta4DDWCPCckmNtbmha6NQP5o7uMk2wicw0QnP4qKsM7hgcjGI9NYN3FLPmgGzMib0mGt7kuZUm9Xwlg/132, createdBy=ab435250494, createdName=lly3676, createdTime=Mon May 31 18:13:04 CST 2021, time=2021-05-31, status=1, ipAttribution=)]
    2021-05-31 lly3676

    很好

    0

相关指南

自身免疫性溶血性贫血诊断与治疗中国专家共识（2017年版）

中华医学会血液学分会红细胞疾病学组 · 2017-04-30

拓展阅读

自身免疫性溶血性贫血诊断与治疗中国专家共识（2017年版）

中华医学会血液学分会红细胞疾病学组 · 2017-04-30